Page 52 - 74_04

M. FRESNO Y COLS. AN. R. ACAD. NAC. FARM

relations between prostanoids-mediated actions and function of cells in
the cardiovascular system is required to clearly understand the benefits
and risks of NSAIDs on cardiovascular diseases.

ACKNOWLEDGMENTS

The authors thank the financial support of Comunidad Autónoma
de Madrid (S-SAL-0159-2006), Ministerio de Educación y Ciencia-
FEDER (SAF 2004-05109, BFU2004-04157 and BFU2007-62659),
European Commission (EICOSANOX integrated project LSH-CT-2004-
005033; and MAIN network of excellence) and Laboratorios del Dr.
ESTEVE S.A.

REFERENCES

(1) WILLIAMS, C. S.; MANN, M. AND DUBOIOS, R. N. (1999) The role of
cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:
7908-7916.

(2) SUBBARAMAIAH, K. AND DANNENBERG, A. J. (2003) Cyclooxygenase 2: a
molecular target for cancer prevention and treatment. Trends Pharmacol. Sci.
24: 96-102.

(3) INIGUEZ, M. A.; RODRIGUEZ, A.; VOLPERT, O. V.; FRESNO, M. AND REDONDO, J.
M. (2003) Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends
Mol. Med. 9: 73-78.

(4) FITZGERALD, G. A.; AUSTIN, S.; EGAN, K.; CHENG, Y. AND PRATICO, D. (2000)
Cyclo-oxygenase products and atherothrombosis. Ann. Med. 32 Suppl 1: 21-
26.

(5) DAVIDGE, S. T. (2001) Prostaglandin H synthase and vascular function. Circ.
Res. 89: 650-660.

(6) ALFRANCA, A.; INIGUEZ, M. A.; FRESNO, M. AND REDONDO, J. M. (2006)
Prostanoid signal transduction and gene expression in the endothelium: role in
cardiovascular diseases. Cardiovasc. Res. 70: 446-456.

(7) BELTON, O. AND FITZGERALD, D. J. (2003) Cyclooxygenase isoforms and
atherosclerosis. Expert. Rev. Mol. Med. 2003: 1-18.

(8) SIMMONS, D. L.; BOTTING, R. M. AND HLA, T. (2004) Cyclooxygenase
isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol.
Rev. 56: 387-437.

16